
How AI could save the broken NHS
Illustrations by Andreion De Castro
You might be frustrated by your recent run-in with a customer service bot but when it comes to healthcare, there's good reason to suggest that a wave of new AI tools could represent hope for our creaking health service, slashing backlogs and catching diseases years or even decades earlier, lengthening lives in the process.
This doesn't mean that your GP or consultant will soon be replaced by a silicon droid; the human element of healthcare will still be very much present. But, behind the scenes, AI is slowly beginning to reveal its prowess.
Last month, Health Secretary Wes Streeting announced that a new AI-powered blood test to detect cancer will be trialled on the NHS. Called miONCO-Dx, it can detect early warning signs of 12 of the most lethal cancers through identifying worrying traces of tiny molecules called microRNAs, which can change the activity of genes.
Proponents of AI's uses in healthcare often describe these tools as either 'a second set of eyes' or 'augmenting what a human doctor can do,' with Colin Rees, Professor of Gastroenterology at Newcastle University saying that he's enormously optimistic about their potential to limit preventable deaths.
'I think AI is going to transform healthcare like almost nothing else ever,' he says. 'Just in diagnostics, it's able to spot new patterns, look at blood tests and scans with a fresh perspective and, of course, it doesn't get tired or make mistakes.'
Already, AI is beginning to make a difference in disease-prevention for a broad range of conditions, from early detection of osteoporosis to helping overstretched radiologists prioritise which patients to examine first.
Let's take a closer look at what's happening right now, how technology may affect different diseases and common conditions, and what's likely to come later down the line.
Lungs
Since early 2022, a growing number of NHS Trusts across the UK have been using tools developed by a company called Annalise.ai to accelerate analysis of the many millions of chest X-rays taken every year.
With the UK currently suffering from a chronic shortage of radiologists – the latest data suggests that the NHS has 30 per cent fewer radiologists than it requires – AI has been trying to pick up the slack. In particular, according to Annalise.ai's CEO and co-founder Dr Aengus Tran, one of the goals has been to slash the time taken to diagnose cases of lung cancer – one of the most common cancers in the UK.
'The NHS has procured our AI across 131 hospitals to essentially run our system over chest X-rays, to see if the AI can find signs of cancer; perhaps subtle signs which might have been missed,' says Dr Tran. 'And if that's the case, those patients will be escalated to the very top of the list.'
The early signs are promising. Data collected from NHS Grampian, in Scotland, suggests that the tool has increased the proportion of lung cancers identified at earlier stages by nearly a third, and the technology is now taking on an even wider remit.
Because Annalise.ai's tools are capable of diagnosing more than 130 different lung-related conditions, from rib fractures to pneumonia to an enlarged heart, some NHS hospitals are already using them to work through their backlog of uninterpreted scans and help prioritise the most urgent cases. 'It means that patients with life-threatening illness and critical conditions are being seen sooner,' says Dr Tran. 'So, for example, in [hospitals in] Manchester, we're seeing that cases of pneumothorax [a collapsed lung] get flagged within less than a day, whereas previously that would have taken five or more days to get to.'
Heart
More than 1.5 million people in the UK have atrial fibrillation, a condition characterised by sporadic bursts of an irregular heartbeat. This can have serious long-term consequences, as blood can begin to collect within the heart, forming clots which can then travel to the brain. As a result, people with atrial fibrillation are also more at risk of suffering a stroke.
The problem, according to Rameen Shakur, a clinical cardiologist and Professor of Genomics & Precision Cardiovascular Medicine at the University of Brighton, is that many of these cases go undetected (an estimated 270,000 people in the UK have undiagnosed atrial fibrillation) because patients do not always present with symptoms when being examined in hospital.
To address this, Prof Shakur created a company called Cambridge Heartwear, which has designed a wearable monitor called Heartsense that records patient's heart rhythms to medical grade standard and checks for signs of atrial fibrillation using inbuilt AI algorithms. The device has since been tested in a clinical trial at a NHS hospital in Worthing, and Prof Shakur is hopeful that it can help to prevent some of the 100,000 strokes that occur each year in the UK alone.
'Once you find out that someone has atrial fibrillation, they can be prescribed anticoagulants [blood thinners] to reduce stroke risk, but that treatment is wholly dependent on catching it and getting a diagnosis,' he says. 'The advantage of this device is that it's discrete and malleable enough that you don't feel it. You can wear it while you're having a shower, when you're sleeping, when you're running to catch a bus – all times when an episode of atrial fibrillation might occur.'
Gut
Earlier this year, the NHS began offering biennial bowel screening to all people aged between 50 and 74, with the aim of detecting and preventing more cases of bowel cancer. According to Prof Rees, the health service now carries out around 700,000 colonoscopy examinations – where a person's bowel is examined using a small camera – every year.
As well as scanning for tumours, one of the aims of this procedure is to identify tiny precancerous warts called polyps, and remove them before they develop into anything more sinister. However, spotting polyps is not always straightforward. 'It requires a lot of concentration,' says Prof Rees. 'The bowel has got lots of folds in it, the large bowel is about a metre long and it has lots of blind spots. And there's very good evidence that missing these things leads to more patients developing cancer.'
To address this issue, Prof Rees recently led a pioneering trial in which gastroenterologists carrying out colonoscopies were given the additional assistance of an AI tool called GI Genius, which had been trained to spot abnormalities within the bowel using powerful neural networks. 'It scans the image which the specialist is looking at on a screen through their scope,' says Prof Rees. 'If it spots an abnormality, it flags it and puts a green box around it. I think of it as being a little bit like spellcheck in Microsoft Word.'
The trial, which involved more than 2,000 patients across 10 NHS Trusts, was successful: 30 per cent more polyps were detected, particularly a form of polyp which is quite notoriously difficult to spot via the naked eye alone. 'We call them sessile serrated polyps,' says Prof Rees. 'They're smaller, flatter polyps but they account for 30 per cent of bowel cancers, so they're particularly dangerous, and we found a significant increase in the detection of these bad guys.'
Bones
For many people in their 50s, a twinge of back pain might be dismissed as a sign of encroaching old age, but, in some cases, it could be a spinal fracture, which represents an early warning sign of degenerative bone disease.
When detected early, osteoporosis – a condition which causes the bones to become weaker and more fragile – is highly treatable. Now a new collaboration between academics, doctors, Royal Osteoporosis Society and the company Nanox.ai is investigating whether the company's technology can pinpoint potentially tell-tale fracture signs.
It could mean that, in future, whenever people in their 50s or 60s receive a CT scan, it will automatically be fed through AI technology to check for hints of osteoporosis.
Eyes
Can Google help prevent one of the most common causes of blindness? An ongoing partnership between Google Health, AI company DeepMind and Moorfields Eye Hospital is attempting to achieve just that through an AI system that aims to predict patients at particularly high risk of age-related macular degeneration – a condition caused by a progressive loss of cells in the retina – with the aim of identifying candidates for preventative treatment.
Because the eye acts as a window to the brain, other AI tools are being developed with the aim of detecting early signs of brain tumours or neurological diseases like Parkinson's, multiple sclerosis and Alzheimer's. According to Dr Siegfried Wagner of the UCL Institute of Ophthalmology and Moorfields Eye Hospital, AI can detect signs of multiple sclerosis through an asymmetry which only becomes apparent when scanning the left and right eyes. He predicts that in the future, such patients could be immediately referred for an MRI scan to investigate further.
'One eye might look completely normal, but AI can pick up a subtle thinning or thickening in the retinal nerve fibres of the other eye,' says Dr Wagner. 'It happens because in multiple sclerosis you get multiple small lesions in the brain, and they're more in one half of the brain than the other. So, you're seeing a reflection of what's happening in the brain, but in the eye.'
Brain
One of the biggest hopes for AI is that it could find a way to predict early warning signs for dementia many years before the onset of symptoms. Indeed, Will Whiteley, Professor of Neurology and Epidemiology at the University of Edinburgh, and a consultant neurologist in NHS Lothian, is leading a major new project to try to train an AI model to do just that, using a bank of CT and MRI scans collected through patients in Scotland over the course of 10 years.
'Right now, neurologists look for shrinkage in parts of the brain called the temporal lob, which are particularly responsible for memory, and a sign of Alzheimer's disease,' says Prof Whiteley. ' Vascular dementia affects the small vessels of the brain, and you can see that on a brain scan, too. But I hope that with these very powerful and flexible AI models, they'll be doing more, finding new things that we hadn't thought of as humans. We're not there yet, but wouldn't it be great if in future all 50-year-olds could take a test to tell you about your risk of dementia and whether you should or shouldn't take a medicine to prevent you getting it in later life?'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Times
20 minutes ago
- Times
Alcohol labels should warn of cancer risk, urge health groups
Bottles of wine and beer should have warning labels stating that alcohol causes cancer, public health experts have said. The World Cancer Research Fund (WCRF), a charity based in London, has launched a campaign urging the government to require companies to put 'bold and unambiguous' health warnings and calorie information on alcoholic drinks. One in 25 cases of cancer in the UK — about 17,000 each year — are caused by alcohol, research shows. Alcohol can cause seven types of cancer, including breast and bowel. A group of health organisations have signed a letter to Sir Keir Starmer demanding a new 'national alcohol strategy', which would include mandatory product labelling. It is also calling for minimum alcohol pricing of 65p per unit in England — the level already in force in Scotland — as well as marketing and advertising restrictions on alcoholic drinks. The organisation said that this would reduce cancer risks as well as cutting other deaths from alcohol, after a 42 per cent increase in alcohol-specific deaths between 2019 and 2023. Alcohol has been shown to cause seven types of cancer OSCAR WONG/GETTY IMAGES Kate Oldridge-Turner, head of policy and public affairs at WCRF, said: 'The evidence is clear: health labelling on alcoholic drinks is urgently needed in the UK to help save lives. 'Health warning labels must be bold, unambiguous and completely separate from any marketing on the product. They should carry strong, clear messages about the health risks, which include the risk of cancer — far beyond vague advice like 'consume in moderation'. 'The goal must be to reduce alcohol use, given it increases the risk of seven types of cancer. Even if people continue to drink on social occasions, cutting down their regular intake would be a major step forward.' A poll of UK adults found that only one in 13 people knew that alcohol increases the risk of cancer and more people thought red wine had health benefits than knew of its cancer risk. Dr Helen Croker, assistant director of research and policy at WCRF, said: 'England prides itself on food safety, so why are our alcohol labelling and marketing restrictions far behind so many other countries? Why hasn't there been a national alcohol strategy in England since 2012? And why do bottles of beer show less information than bottles of orange juice? It is not mandatory in the UK to put health warnings on labels of alcoholic drinks MATTHEW HORWOOD/GETTY IMAGES 'We urgently need proper public awareness so that people understand the risks that come with drinking alcohol.' Sir Ian Gilmore, chairman of the Alcohol Health Alliance, said: 'One of the reasons public awareness is so low is that we are being kept in the dark about the true cost of drinking. People have the right to know the full picture so that they can make informed choices about what they consume. 'To reduce the impact of alcohol on our health, we need change at a national level. We urgently need a national alcohol strategy to open up honest conversations about the risks of alcohol, while putting measures in place to tackle and prevent its harms.'


Medical News Today
21 minutes ago
- Medical News Today
Rapamycin may extend lifespan as effectively as dietary restrictions
Research is ongoing about potential strategies to prolong life. A meta-analysis found that the drug rapamycin prolongs life in several vertebrate appeared to prolong life at a level similar to dietary restrictions. How to prolong life is a key area of scientific research. Experts are interested in medications that have the potential to boost longevity.A recent meta-analysis published in Aging Cell explored how rapamycin and metformin influenced longevity among several results confirmed that dietary restriction appears to prolong life and that rapamycin offers similar benefits. Researchers also found that metformin did not seem to prolong life. More research is required to see how rapamycin might help boost longevity in people. Rapamycin: Does it increase lifespan?In this paper, researchers note that decreasing food intake without malnourishment appears to prolong life but that this strategy is difficult for people to stick to. Thus, looking into possible medications that produce similar effects is an area of research. The two medications that were the focus of this analysis were rapamycin and metformin. According to the National Cancer Institute, rapamycin has a few functions, such as being an immunosuppressant and antibiotic, and it can help people who get helps with type 2 diabetes management. This analysis involved a systematic literature search to find relevant data. The final analysis included data from 167 papers looking at eight total vertebrate species, seeking to see how both medications affected longevity and how they compared to dietary extracted information on average and median lifespan from the papers. For this analysis, the two types of dietary restriction were caloric reduction and fasting, and researchers also sought to see if the results differed based on the sex of the animals involved. The data came from animals like mice, rats, turquoise killifish, and rhesus macaques. Overall, there were more males studied than females. There was also the most data on dietary restriction, and the most common type of dietary restriction was decreasing the number of calories. Regarding dietary restriction, the findings suggested great variation regarding the effects. Overall, researchers found that dietary restriction and rapamycin had a similar impact and appeared to contribute to prolonged life. Metformin appeared to only have a minimal impact on life from one metformin model, there appeared to be no consistent differences between male and female animals regarding longevity. Study author Zahida Sultanova, PhD, a Leverhulme Early Career Research Fellow with the University of East Anglia, in the United Kingdom summarized the key findings of the study to Medical News Today: 'We checked whether the two best-known 'diet-mimic' drugs increase lifespan similar to eating less in animals. By pooling data from 167 studies, we found that rapamycin is almost as reliable as eating less for increasing lifespan, whereas metformin is not. In other words, a compound that was extracted from soil bacteria 50 years ago seems able to copy many of the biological effects of a permanent diet, at least in lab animals.'Do the same benefits apply to people?This research analyzed animal data but did not include data about people. Additionally, most of these studies involved these animals in a laboratory setting and only looked at a small number of meta-analysis was also the work of only three researchers, sometimes with only one researcher doing a component of the work, which could have impacted the had the least amount of data on metformin, so more research about this medication might be helpful. They also operated under the assumption that if a paper did not specify male or female subjects, it was a mixed group, which could have been incorrect. The authors further note that the 'results were sensitive to how lifespan was reported.' Researchers also acknowledge strong publication bias and a lot of heterogeneity. Additionally, the type of measure used in study reporting affected results. In one measurement, the impact on life extension disappeared for the most part, the authors did not find a consistent difference in results based on the sex of the animals. They explain this could be because of 'differences in taxonomic groups studied […] and the calculated effect size.' Sultanova noted the following cautions regarding the findings: 'This study includes a high number of scientific studies conducted on different organisms such as mice, fish and monkeys. However, survival results in humans are not included because these drugs were not tested in humans for lifespan extension. Even if they are, the studies will take a long time considering the length of human lifespan. So, we do not recommend people to take rapamycin before the results of human trials consistently show that there are no side effects.'Why is it hard to study rapamycin in humans?Researchers suggest the need for research involving other species in natural and laboratory settings. They also note the need to understand the difference in impact for 'different strains of the same species exposed to the same treatment.'Future research can further focus on the differences between rapamycin and metformin and why they impact lifespan differently. More research into the differences in rapamycin's results in males and females could be helpful as well. More research can be done to see if rapamycin can promote prolonged life in people, but there may be some challenges in this Ali, MD, a board-certified general surgeon, bariatric surgeon, and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, who was not involved in the study, told MNT that it 'shows the contribution of the immune system to lifespan, as rapamycin is an immunosuppressive medication.'According to him: 'The most logical next step is to explore the findings in humans; however, this would be a difficult study to design as rapamycin is a medication used in specific cancers and organ transplant and has significant side effects.'Despite this, the results show a potential benefit of rapamycin that warrants more explained that: 'Clinically, that puts rapamycin (and the mTOR pathway it targets) at the front of the queue for future anti-ageing therapies in humans. The compound had already been used for organ-transplant patients, so medical professionals understand its potential side effects.''The next step is waiting for the results of ongoing human trials that test lower and intermittent doses of rapamycin and refining the compound to 'rapalog' versions that keep the benefits while omitting side-effects such as immune suppression,' she told us.'Another important next step would be developing drugs that are similar in structure and function to rapamycin but without the side-effects. Scientists have already started refining rapamycin and producing the so-called rapalogs,' Sultanova noted.

Finextra
31 minutes ago
- Finextra
How Can Banks Harness Data to Drive Innovation in the Market?
Joining the FinextraTV studio at the Temenos Community Forum 2025, Rodrigo Silva, President, Americas, Temenos, and Geoff Vona, Vice President and CTO, EQ Bank, discussed the benefits of co-innovation for banks. Considering the increasingly important role of data and AI, they explain how technology can help banks to enhance customer experiences and launch innovative new products faster.